PriceTargets.com logo

Eupraxia Pharmaceuticals - EPRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.80
  • Forecasted Upside: 160.61%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$6.83 As of 10/30/2026 05:00 PM ET
▼ -0.42 (-5.79%)

This chart shows the closing price for EPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eupraxia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPRX

Analyst Price Target is $17.80
▲ +160.61% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Eupraxia Pharmaceuticals in the last 3 months. The average price target is $17.80, with a high forecast of $25.00 and a low forecast of $11.00. The average price target represents a 160.61% upside from the last price of $6.83.

This chart shows the closing price for EPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Eupraxia Pharmaceuticals. This rating has held steady since March 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
5/3/2026
  • 2 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/20/2026OppenheimerReiterated RatingOutperform ➝ Outperform
10/15/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
10/1/2026HC WainwrightReiterated RatingBuy ➝ Buy$11.00
9/24/2026Stifel NicolausSet Target$25.00
9/24/2026WedbushInitiated CoverageOutperform$17.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/15/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
6/25/2026OppenheimerInitiated CoverageOutperform$17.00
5/21/2026Stifel NicolausInitiated CoverageBuy$25.00
5/7/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
5/4/2026HC WainwrightReiterated RatingBuy ➝ Buy$11.00
4/22/2026HC WainwrightReiterated RatingBuy ➝ Buy$11.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/23/2026William BlairInitiated CoverageOutperform
3/17/2026Zacks ResearchDowngradeHold ➝ Strong Sell
3/17/2026HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $11.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/15/2026Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$11.00 ➝ $19.00
1/9/2026HC WainwrightReiterated RatingBuy ➝ Buy$12.00
12/11/2025Lifesci CapitalUpgradeStrong-Buy
10/29/2025Leede FinancialUpgradeStrong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00
7/24/2025Cantor FitzgeraldInitiated CoverageOverweight$11.00
6/26/2025HC WainwrightInitiated CoverageBuy$12.00
6/26/2025HC WainwrightInitiated CoverageBuy$12.00
6/16/2025Canaccord Genuity GroupInitiated CoverageSpeculative Buy
2/21/2025Craig HallumInitiated CoverageBuy$12.00
11/14/2024Rodman & RenshawUpgradeStrong-Buy
11/14/2024Rodman & RenshawInitiated CoverageBuy$9.00
5/22/2024Raymond James FinancialUpgradeStrong-Buy
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/1/2026
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Eupraxia Pharmaceuticals logo
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.
Read More

Today's Range

Now: $6.83
Low: $6.41
High: $7.10

50 Day Range

MA: $7.59
Low: $6.34
High: $9.10

52 Week Range

Now: $6.83
Low: $5.25
High: $9.32

Volume

1,222,987 shs

Average Volume

789,302 shs

Market Capitalization

$444.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Eupraxia Pharmaceuticals?

The following Wall Street research analysts have issued reports on Eupraxia Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Lifesci Capital, Oppenheimer Holdings, Inc., Stifel Nicolaus, Wall Street Zen, Wedbush, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for EPRX.

What is the current price target for Eupraxia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Eupraxia Pharmaceuticals in the last year. Their average twelve-month price target is $17.80, suggesting a possible upside of 160.6%. Stifel Nicolaus has the highest price target set, predicting EPRX will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Eupraxia Pharmaceuticals in the next year.
View the latest price targets for EPRX.

What is the current consensus analyst rating for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals currently has 1 sell rating, 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for EPRX.

What other companies compete with Eupraxia Pharmaceuticals?

Other companies that are similar to Eupraxia Pharmaceuticals include Zenas BioPharma, Intellia Therapeutics, Hemab Therapeutics, Maze Therapeutics and Mesoblast. Learn More about companies similar to Eupraxia Pharmaceuticals.

How do I contact Eupraxia Pharmaceuticals' investor relations team?

Eupraxia Pharmaceuticals' physical mailing address is 2067 Cadboro Bay Road, Victoria, BC, V8R 5G4. The company's listed phone number is 250-590-3968 and its investor relations email address is [email protected]. The official website for Eupraxia Pharmaceuticals is www.eupraxiapharma.com. Learn More about contacing Eupraxia Pharmaceuticals investor relations.